Clinical commissioning policy: Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

Document first published:: 21 October 2022
Page updated:: 11 November 2022
Topic:: Specialised commissioning
Publication type:: Policy or strategy

Alglucosidase alfa is recommended as a not for routine commissioning treatment option for infantile-onset Pompe disease (IOPD) within the criteria set out in this document.

Document

Clinical commissioning policy: Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

Clinical commissioning policy: Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

PDF
116 KB

Document

Clinical panel report: Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

Clinical panel report: Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

PDF
38 KB

Document

Clinical priorities advisory group summary report: Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

Clinical priorities advisory group summary report: Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

PDF
80 KB

Document

Evidence review: Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

Evidence review: Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

PDF
439 KB

Document

Engagement report: Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

Engagement report: Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

PDF
104 KB

Document

Equality and Health Inequalities Impact Assessment (EHIA): Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

Equality and Health Inequalities Impact Assessment (EHIA): Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)

PDF
102 KB